Johnson & Johnson (NYSE:JNJ) Shares Sold by Jamison Private Wealth Management Inc.

Jamison Private Wealth Management Inc. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,350 shares of the company's stock after selling 3,187 shares during the quarter. Johnson & Johnson comprises 2.2% of Jamison Private Wealth Management Inc.'s portfolio, making the stock its 8th largest position. Jamison Private Wealth Management Inc.'s holdings in Johnson & Johnson were worth $14,486,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. purchased a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson during the 4th quarter valued at approximately $33,000. Bernard Wealth Management Corp. purchased a new stake in Johnson & Johnson during the 4th quarter worth approximately $36,000. Finally, Runnymede Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $38,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research note on Wednesday, April 16th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Barclays lowered their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a report on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $0.14 during trading hours on Wednesday, hitting $152.33. The company had a trading volume of 7,149,773 shares, compared to its average volume of 8,004,092. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market cap of $366.52 billion, a P/E ratio of 16.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The business has a fifty day simple moving average of $153.99 and a 200-day simple moving average of $153.68.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.